title: [Antitumor effect of paclitaxel for gastric cancer is AUC dependent].
abstract: Paclitaxel (PTX), which is used for ovarian cancer, lung cancer, breast cancer and gastric cancer, is administered at a dose of 210 mg/m(2) once every three weeks. However, WHO grade 3-4 hematological and non-hematological toxicity occurred frequently in this manner. In recent studies about ovarian cancer and lung cancer, a schedule in which PTX was given weekly could have the same or better efficacy, with fewer side effects. The response rate of PTX administered every three weeks for gastric cancer, was 23.3 to approximately 28.0%, while that of PTX administered weekly was 24.0 to approximately 25.8%. Because of fewer adverse events, weekly PTX is widely used for gastric cancer in Japan. To prove the validity of PTX weekly administration, we performed a study using six specimens removed surgically and one specimen collected from ascites. A chemosensitivity test was performed on the basis of two assumptions: a high concentration for a short time, and a low concentration for a long time. A similar PTX effect was obtained when the AUC was equal. In this study, we demonstrated that the effect of low-dose PTX was equal to the effect of high-dose PTX in gastric cancer.
authors.affiliation: Dept. of Surgery, Nippon Medical School, Chiba Hokusou Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yamada
authors.forename: Noritake
authors.initials: N
authors.lastname: Tanaka
authors.forename: Kiyonori
authors.initials: K
authors.lastname: Furukawa
authors.forename: Kimiyoshi
authors.initials: K
authors.lastname: Yokoi
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Ishikawa
authors.forename: Tomoko
authors.initials: T
authors.lastname: Seya
authors.forename: Kouji
authors.initials: K
authors.lastname: Horiba
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kanazawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Shirakawa
authors.forename: Hidenori
authors.initials: H
authors.lastname: Kudoh
authors.forename: Michihiro
authors.initials: M
authors.lastname: Koizumi
authors.forename: Masato
authors.initials: M
authors.lastname: Yoshioka
authors.forename: Seiichi
authors.initials: S
authors.lastname: Shinji
authors.forename: Miwako
authors.initials: M
authors.lastname: Katsuta
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Ohaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Tajiri
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019540:Area Under Curve; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel